Catalyst

Slingshot members are tracking this event:

Genentech’s Cancer Immunotherapy Tecentriq (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY Community voting in process

Additional Information

Clinical Data In a Phase II study, IMvigor 210, TECENTRIQ™ (atezolizumab) shrank tumors (objective response rate, ORR) in 24 percent (n=28) of people with locally advanced or metastatic urothelial carcinoma (mUC) who have not received a prior treatment (first-line) and who were ineligible for cisplatin-based chemotherapy. Of those people who responded, 75 percent (n=21) continued to respond to treatment and the median duration of response (DOR) had not been reached at the time of analysis. Seven percent (n=8) of all people in the study achieved a complete response (CR). The median overall survival (OS) was 14.8 months. The safety profile of TECENTRIQ was consistent with that observed in an earlier analysis of the study, as well as in other studies of TECENTRIQ as a monotherapy.
http://www.gene.com/...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tecentriq, Atezolizumab, Shrank Tumors, Untreated Advanced Bladder Cancer, Advanced Bladder Cancer